



Proteomics International

LABORATORIES LTD

28 September 2020

The Manager
Market Announcements Office
Australian Securities Exchange

Dear Manager,

CHANGE OF DIRECTOR'S INTEREST NOTICE

Proteomics International Laboratories Ltd (ASX:PIQ) advises that Founder and Managing Director, Dr Richard Lipscombe has transferred 710,000 shares from his personal holding to his superannuation fund.

An Appendix 3Y – Change of Director's Interest Notice is attached.

This announcement was authorised to be given to ASX by Dr Richard Lipscombe (Managing Director) on behalf of the Board of Proteomics International Laboratories Ltd.

Yours faithfully,

Karen Logan
Company Secretary

Proteomics International Laboratories Ltd

ABN 78 169 979 971

Box 3008, Broadway, Nedlands, WA 6009, Australia

T: +61 8 9389 1992 | E: enquiries@proteomicsinternational.com | W: www.proteomicsinternational.com

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Proteomics International Laboratories Ltd
ABN	78 169 979 971

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Richard Lipscombe
Date of last notice	9 July 2020

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct and indirect
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	Bjouxz Pty Ltd <The Loz Superannuation Fund> Dr Lipscombe is beneficiary of the superannuation fund and sole director and shareholder of the trustee.
Date of change	24 September 2020
No. of securities held prior to change	<i>Direct</i> 9,872,115 fully paid ordinary shares (Shares) <i>Indirect</i> 9,176,590 Shares
Class	Shares
Number acquired	710,000 Shares.
Number disposed	710,000 Shares.
Value/Consideration <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	\$344,350 (\$0.485 per Share).

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

No. of securities held after change	<i>Direct</i> 9,162,115 Shares <i>Indirect</i> 9,886,590 Shares
Nature of change <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	Off-market transfer from direct holding to superannuation fund.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	Not applicable.
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	
Interest acquired	
Interest disposed	
Value/Consideration <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	
Interest after change	

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	No.
If so, was prior written clearance provided to allow the trade to proceed during this period?	Not applicable
If prior written clearance was provided, on what date was this provided?	Not applicable

⁺ See chapter 19 for defined terms.